Work

Bevacizumab for the treatment of metastatic colorectal cancer complicated by abdominal aortic aneurysm and mural thrombus: a case report

Year: 2024

Type: article

Abstract: Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), was the first anti-angiogenic agent incorporated into metastatic colorectal cancer treatment strategies and demonstrated broad-spectrum anti-tumor efficacy. Commonly reported adverse events include hypertension, proteinuria, gastrointestinal perforation, bleeding, and thromboembolism. However, there are only a few reports on abdominal aortic aneurysms (AAA) as a complication of bevacizumab therapy. Given the high risk of fatal rupture with AAA, we present a case of bevacizumab-associated AAA to raise clinician awareness of this possible, rare, and serious adverse reaction.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2024.1416349

Authors: Yujun Li, Tong Wu, Muhammad Muddasar Saeed, Xiaonan Cui

Institutions: Dalian Medical University, First Affiliated Hospital of Dalian Medical University

Language: English

Topic: Aortic aneurysm repair treatments

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,295